Background. The purpose of our study was to evaluate the incidence and outcome of invasive fungal infection (IFI) among patients who underwent autologous or allogeneic hematopoietic stem cell transplantation (HSCT) at 11 Italian transplantation centers.
morbidity and mortality among patients with hematologic malignancies, particularly in those affected by acute myeloid leukemia [1] [2] [3] [4] [5] and in persons who undergo hematopoietic stem cell transplantation (HSCT) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Although attention has mainly focused on identifying risk or prognostic factors in HSCT recipients [6, 7, 19, 20] , few attempts have been made to assess the real incidence of IFI (table 1) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] .
Recent reports, which have mainly been based on Martino et al. [7] 1996-2000 395 32 (8.1) 22 (59) Cornet et al. [10] 1994-1998 NR 199 (12.8) NR
Grow et al. [9] 1997-1998 93 14 (15.1) 5 (36) Fukuda et al. [15] 1997 autopsy data, have revealed a progressive increase in the overall incidence of IFI, particularly those caused by molds, and there has been an increasing number of episodes of IFI due to Aspergillus species other than Aspergillus fumigatus, to Fusarium species, and to Zygomycetes species [13, [21] [22] [23] . This change in epidemiological trends may be related not only to a real increase in the number of IFI episodes due to these emerging pathogens, but also to more-accurate diagnostic tools, which reduce the probability of misdiagnosis, or to prior widespread administration of fluconazole prophylaxis, which provides coverage against many Candida strains but not against Aspergillus species or other molds [6] . The risk for IFI after HSCT depends on the graft source (i.e., peripheral stem cells, bone marrow, or cord blood), the presence of acute or chronic graft-versus-host disease (GVHD), administration of steroids, the presence of cytomegalovirus (CMV) disease, and eventual antifungal prophylaxis [24, 25] . The risk of IFI is greater among allogeneic HSCT recipients, among whom the incidence of proven or probable IFI is reported to be in the range of 5%-18% [8] [9] [10] [11] [12] [13] [14] [15] [16] , compared with 0%-1.1% [9] [10] [11] [12] , even after CD34 + selection, among autologous HSCT recipients (table 1) [26] . Despite identification of these risk factors, the incidence of IFI is probably underestimated in the context of transplantation, because an unknown number of patients die without the pathogen being identified [27, 28] , and mortality rate data are frequently based on metaanalyses [20] .
In the present study, we investigated the current incidence of IFI and IFI-related mortality rates among inpatients who underwent autologous or allogeneic HSCT during 1999-2003 in Italian transplantation centers.
PATIENTS AND METHODS
We performed a retrospective study in 11 tertiary care centers or university hospitals in Italy to assess the incidence of IFI Downloaded from https://academic.oup.com/cid/article-abstract/45/9/1161/369561 by guest on 24 January 2019 [29] , with modification made for additional diagnostic tools, such as the galactomannan test. Only infections that were classified as proven or probable were included in the data analysis.
Study design. Each transplantation center completed a questionnaire eliciting the following data: the number of allogeneic and autologous HSCTs performed during 1999-2003 at each center, the stem cell source (i.e., bone marrow, peripheral blood, or umbilical cord) for each transplantation, and data on all IFI episodes experienced by HSCT recipients. For each patient, we requested the following information: age, sex, disease and disease stage at time of HSCT, type of HSCT (autologous or allogeneic), type of graft (from a matched, related donor; matched, unrelated donor; or a mismatched, related donor), conditioning regimen, presence or absence of a central venous catheter, CMV serologic data, presence of acute or chronic GVHD, history of fungal infection, receipt of antifungal prophylaxis, diagnostic evaluation findings, date of IFI diagnosis, time from HSCT to diagnosis of IFI, fungal species isolated, in vivo and postmortem microbiological and histological findings, and outcome (assessed on the 150th day after IFI diagnosis).
In each participating center, antifungal prophylaxis consisted of itraconazole or fluconazole in addition to local agents. Transplantation centers did not change their guidelines during the study period. Similar therapeutic protocols that reflected the current guidelines of the Infectious Diseases Society of America [30, 31] were used by all centers throughout the study.
Multiple IFI episodes in any individual patient were counted as separate infections unless they were caused by the same pathogen. Overall and IFI attributable mortality rates (AMRs) were estimated. For each patient, a correct analysis of any condition that could have contributed to death was required from attending physicians; the IFI AMR was finally defined as a progression of sepsis-related symptoms or of involved organ failure in the absence of other comorbid conditions believed to cause death. Statistical analysis. Univariate analysis, which was performed using the x 2 test, and multivariate analysis, which was determined using logistic regression analysis, identified variables predicting mortality. Independent variables tested in the univariate analysis included sex, age group (16-35, 36-49, and 150 years), autologous or allogeneic HSCT, source of stem cells (peripheral blood, bone marrow or umbilical cord), CD34 + selection, disease (acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, non-Hodgkin lymphoma, Hodgkin disease, multiple myeloma, and severe aplastic anemia), complete remission at transplantation, presence or absence of a central venous catheter, time to IFI after transplantation, site of infection, pathogen (mold or yeast), antifungal prophylaxis (local or systemic), prophylactic agent (fluconazole, itraconazole, voriconazole, and/or liposomal amphotericin B), and center in which the patient was observed. For allogeneic HSCT, we also analyzed the type of graft (from a matched, related donor; a matched, unrelated donor; or a mismatched, related donor), use of total body irradiation as part of the patient's conditioning regimen (yes or no), presence or absence of acute or chronic GVHD, and CMV serologic test results. Variables with incomplete data sets were not included.
Multivariate analysis was performed using a logistic regression model in which goodness of fit was assessed with the Hosmer and Lemeshow test [32] . The model included only variables with a univariate P value !.25, applying the stepwisewith-backward-elimination method. Adjusted ORs and 95% CIs were calculated.
We repeated the univariate and the multivariate analyses after stratification based on type of graft (allogeneic vs. autologous HSCT) and pathogen (molds vs. yeasts). Furthermore, aspergillosis was analyzed only in allogeneic HSCT recipients. Statistical significance was set at . The analysis was per-P ! .05 formed using SPSS software for Windows, version 13.0 (SPSS).
RESULTS
During the 5-year study, 3228 patients underwent HSCT at 11 transplantation centers (1979 underwent autologous HSCT, and 1249 underwent allogeneic HSCT). One hundred twentyone episodes of IFI (incidence, 3.7%; 95% CI, 3.1%-4.4%) were documented; 59 (49%) were proven cases, and the others were considered to be probable infections. The clinical characteristics of the patients are reported in table 2. The overall incidence of IFI increased during the study period, particularly from 2002 to 2003 (relative risk [RR], 2.24; 95% CI, 1.29-3.87; P p ) (figure 1). Molds were responsible for 91 proven and .003 probable episodes (incidence, 2.8%; 95% CI, 2.3%-3.4%), and yeasts were responsible for 30 proven episodes (incidence, 0.9%; 95% CI, 0.6%-1.3%). The lung was the most frequently affected site with regard to Aspergillus infection (68 cases). Mold infections disseminated to multiple sites in 14 cases (table 2) . Sepsis occurred in 33 patients; 30 cases were due to Candida species, and 3 were due to Fusarium species.
The overall mortality rate for IFI was 2.4% (79 of 3228 patients; 95% CI, 2.0%-3.0%), and the overall IFI AMR was 65.3% (79 of 121 cases; 95% CI, 56.5%-73.4%), with significant differences when we compared mold and yeast infections (table  3) : the aspergillosis AMR was significantly higher than the candidemia AMR (72.1% vs. 50%;
). Infections with P p .043 molds other than Aspergillus species were associated with a low AMR (40%; 95% CI, 7.3%-81.8%). The aspergillosis AMR varied during the study period, decreasing (albeit not significantly) from 81% in 1999 to 59% in 2003 (RR, 0.73; 95% CI, 0.50-1.06;
). P p .12 Univariate analysis revealed that the following parameters had no significant influence on outcome: age, sex, disease, transplantation center, complete remission at transplantation, stem cell source, site of infection, presence of a central venous catheter, and receipt of systemic prophylaxis with fluconazole, itraconazole, liposomal amphotericin B, or voriconazole. Variables that negatively influenced outcome were allogeneic HSCT versus autologous HSCT (mortality rate, 72% vs. 35%; P p ), mold infection versus yeast infection (mortality rate, 70% .001 vs. 50%; ), and systemic antifungal prophylaxis versus P p .043 topical prophylaxis (mortality rate, 71% vs. 48%;
). P p .027 Multivariate analysis confirmed that allogeneic HSCT was associated with a worse prognosis than was autologous HSCT (OR, 4.64; 95% CI, 1.74-12.38;
). P ! .01 Allogeneic HSCT. Among recipients of allogeneic HSCTs, an HLA-matched, related donor was the source of stem cells in 747 (60%) of 1249 transplantations. HLA-mismatched, related donors or matched, unrelated donors were the sources for 181 patients (14%) and 321 patients (26%), respectively. Seven patients had experienced a fungal infection (probable aspergillosis) before transplantation. Among the allogeneic HSCT recipients, 98 proven or probable IFIs were documented (incidence, 7.8%; 95% CI, 6.5%-9.4%). Most cases occurred among recipients of transplants from matched, related donors (table 4). As for the underlying hematological malignancies, acute lymphoid or myeloid leukemia were associated with the highest risk (66% of all cases). Most cases of IFI infection (61 [62%] of 98) occurred in the first 100 days after transplantation; 84 cases (86%) were due to molds, and 14 (14%) were due to yeasts. The majority of mold infections (79 [94%] of 84) were caused by Aspergillus species. The species was identified in 36% of Aspergillus isolates; A. fumigatus was the most common pathogen (16 of 84 episodes) (table 5) . Zygomycetes and Scedosporium species were each responsible for 1 episode of IFI, and Fusarium species were responsible for 3. A significant increase in the annual incidence of aspergillosis was observed during the study period (RR, 2.47; 95% CI, 1.19-5.13; ) (figure 1). P p .01 All yeast infections were caused by Candida species (14 episodes), as diagnosed by blood culture. Candida albicans was the etiologic agent in 7 episodes, and non-albicans species of Candida were responsible for the other 7 episodes.
The overall mortality rate for fungal infection was 5.7% (95% CI, 4.5%-7.1%), with an IFI AMR of 72% (95% CI, 63.0%-80.6%; 71 deaths among 98 cases of proven or probable IFI). The overall rate of mortality due to aspergillosis was 4.9% (95% CI, 3.8%-6.2%), with an Aspergillus infection AMR of 77.2% (95% CI, 67.0%-85.5%; 61 deaths among 79 cases of proven or probable Aspergillus infection). Two of the 3 Fusarium infections were fatal, as was the infection caused by Zygomycetes species. The patient who had Scedosporium infection survived. The overall rate of mortality due to Candida infection was 0.6% (95% CI, 0.3%-1.2%), with a Candida infection AMR of 57% (95% CI, 31.1%-80.4%; 8 deaths among 14 episodes of Candida infection). There were no differences in the AMRs for C. albicans infection (4 of 7 cases were fatal) and non-albicans Candida infection (4 of 7 cases were fatal).
Among the 98 patients with IFI, the majority received both oral polyenes and systemic antifungal drugs, particularly azoles. Distribution of fungal agents did not vary among topical or systemic prophylaxis recipients. At one transplantation center, 6 breakthrough cases of aspergillosis occurred while voriconazole was being administered as secondary antifungal prophylaxis. All of these patients had received antifungal treatment during a previous therapeutic phase because of the occurrence of IFI before the HSCT procedure (1 proven, 2 probable, and 3 possible IFIs). Systemic prophylaxis was associated with a significantly higher mortality rate (78% vs. 52%; ), as confirmed by P p .02 multivariate analysis (OR, 4.89; 95% CI, 1.53-15.60;
). P p .01 The AMR was higher in patients whose hematological malignancy was not in complete remission at the time of transplantation (80% vs. 64%;
). More patients died of fungal P p .067 infection during the first 100 days after transplantation (79%, compared with 62% for у101 days after transplantation;
). P p .076
Univariate analysis was performed for aspergillosis in allogeneic HSCT recipients alone (79 cases) and revealed that fluconazole prophylaxis was negatively correlated with outcome ( ). Patients who underwent total body irradiation in P p .042 the conditioning regimen had a better prognosis ( ). P p .03 Multivariate analysis confirmed this finding and indicate that the following variables influenced outcome: age 136 years, presence of a central venous catheter, and receipt of a transplant from a matched, unrelated donor (table 6) .
Autologous HSCT. Among patients who underwent autologous HSCT, 23 proven or probable IFIs were documented; 7 were due to molds, and 16 were due to yeasts. The overall incidence was estimated to be 1.2% (95% CI, 0.08%-1.7%). Mold infections were all caused by Aspergillus species, whereas yeast infections were all caused by Candida species. The agent was C. albicans in 6 episodes (33%) and non-albicans species of Candida in 10 episodes (67%). The overall mortality rate for fungal infection among autologous HSCT recipients was 0.4% (95% CI, 0.2%-0.8%), with an IFI AMR of 34.8% (95% CI, 17.6%-55.5%; 8 deaths among 23 patients with proven or probable fungal infection). The overall rate of mortality due to Candida infection was 0.4% (95% CI, 0.2%-0.7%; 7 deaths among 1979 autologous HSCT recipients), with a Candida infection AMR of 43.8% (95% CI, 21.5%-68.0%; 7 deaths among 16 patients with Candida infection). Outcome was poorer among patients with infections due to non-albicans Candida strains than among those with C. albicans infection, although the difference was not significant (50% vs. 33%;
). P p .5 Only 1 patient (!0.1%; 95% CI, 0.02%-0.2%) died of aspergillosis; the aspergillosis AMR was 14.3% (95% CI, 0.7%-53.0%; 1 death among 7 patients with proven or probable Aspergillus infection). Univariate and multivariate analysis did not identify any significant variable influencing outcome.
Comparison between the 2 HSCT procedures. The overall incidence of IFI was significantly higher among allogeneic HSCT recipients than among autologous HSCT recipients (7.8% vs. 1.2%; RR, 6.75; 95% CI, 4.31-10.57;
). As-P ! .001 pergillosis was significantly more common after allogeneic HSCT than after autologous HSCT (6 ). P p .67 It is worth noticing that all IFIs appeared soon after transplantation in autologous HSCT recipients, whereas patients receiving allogeneic HSCT continued to be at risk even after 100 days (table 7) .
DISCUSSION
Our data confirm that aspergillosis is the major invasive fungal complication in allogeneic HSCT recipients but not in autologous HSCT recipients [9] [10] [11] [12] . A. fumigatus was the most frequently isolated species. This finding does not concur with recent reports showing that molds other than Aspergillus species have been increasing in frequency over the past decade [23, 33] . In our population, infections due to other molds were extremely rare, with a ratio of infection due to Aspergillus species to that due to other molds of approximately 15:1. The rarity precludes any conclusion on the mortality rate of these other molds.
Among the HSCT recipients in our study, the incidence of IFI increased in 2002 and 2003, whereas the IFI AMR seems to have decreased. In our view, this was associated with the use of a better and more timely means of diagnostic evaluation, particularly for mold infections. More frequent use of highresolution CT and better correlation of clinical pictures with serologic test results [34] probably led to detection of more infections and to use of more-appropriate therapeutic approaches. Furthermore, changes in transplantation practices, such as the use of alemtuzumab for GVHD prophylaxis or the use of reduced-intensity conditioning, which is usually associated with a higher incidence of chronic GVHD, may also have facilitated IFI, because these measures had already been implemented (although they had not been implemented at every center at the time of our study).
The incidence of mold infection was low among patients who underwent a total body irradiation-based conditioning regimen, possibly because total body irradiation favors engraftment and neutrophil recovery and reduces posttransplantation relapse [11] .
The onset of IFI occurred at different times for each transplantation procedure. In autologous HSCT recipients, neutropenia was the major risk factor, whereas in allogeneic HSCT, IFI also developed in the late posttransplantation period because of persistent immune deficiency, which was mainly secondary to GVHD and its therapy. Such differences were particularly evident with regard to yeast infections.
A meta-analysis of 50 studies of aspergillosis revealed mortality rates of up to 90% among allogeneic HSCT recipients [20] . Overall, in our study of autologous and allogeneic HSCT, the aspergillosis AMR was ∼70%, but it was dramatically higher for allogeneic HSCT recipients (77% vs. 14%). The influence of systemic antifungal prophylaxis with fluconazole on outcome for patients who developed invasive aspergillosis was suspected at univariate analysis, but it was not confirmed by multivariate analysis. The role of this prophylaxis is still debated: it probably Downloaded from https://academic.oup.com/cid/article-abstract/45/9/1161/369561 by guest on 24 January 2019 protects patients against yeasts but could favor the onset of very aggressive Aspergillus infections [25] . A more recent study hypothesizes that pretransplantation exposure to fluconazole inhibits subsequent killing activity of amphotericin B [35] . Upton et al. [36] reported that the outcome of aspergillosis recently improved as a result of advances in clinical practice, such as more prompt diagnosis, use of peripheral blood stem cells in transplants, and widespread use of voriconazole. None of these variables influenced the outcome in our analysis of aspergillosis. Conflicting results probably reflect the difficulty of obtaining clear conclusions from retrospective studies and the presence of many host variables and comorbidities (e.g., disease stage at transplantation, GVHD, and CMV infection) that could account for differences in the results of observational studies.
Candida species were the only yeast pathogens that we observed. Interestingly, the incidence of candidemia was similar among allogeneic and autologous HSCT recipients, suggesting that the type of transplantation was not a risk factor. Although the incidence was low, the Candida-related mortality rates among allogeneic HSCT and autologous HSCT recipients were higher than those noted in other reports [6] [7] [8] ; this is possibly associated with the systematic administration of prophylaxis with fluconazole at almost all of the centers, resulting in induced selection of drug-resistant Candida strains. In fact, Marr et al. [6] reported that the primary cause of death associated with candidemia was non-albicans strains of Candida, which are generally more aggressive and difficult to treat. The influence of previous antifungal prophylaxis with fluconazole on the distribution of different Candida species has already been ascertained elsewhere [37, 38] . Furthermore, it recently has been reported that fluconazole may also induce resistance among C. albicans strains [39] . However, among the patients who underwent allogeneic HSCT in our study, the ratio of C. albicans to non-albicans Candida species was 1:1, and the Candida infection AMR was equally distributed in both groups; consequently, the use of fluconazole cannot be the only explanation for such trends. It is possible that the delayed identification of yeasts on blood culture could have played a role.
Despite the limits of our statistical analysis associated with the few cases that we analyzed, our data confirm that patients who undergo allogeneic HSCT have a high risk of developing IFI and that the IFI AMR remains very high. This information may help hematologists plan means of preventing aspergillosis in allogeneic HSCT recipients by using new, wide-spectrum antifungal agents and improve the management of fungal complications [40] [41] [42] .
